The Stamford Hospital
- Type
- Teaching hospital
- Where
- Stamford, CT
- Medicare CCN
- 070006
- Received
- $424,199 in 55 records, 2023 ($52,368 general, $371,830 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: STAMFORD HOSPITAL Fuzzy (name and state)
- Plan sponsor: STAMFORD HOSPITAL Fuzzy (name and state)
- Federal award recipient: STAMFORD HOSPITAL Fuzzy (name and state)
- Federal award recipient: STAMFORD HOSPITAL Fuzzy (name and state)
- Lobbying client: STAMFORD HOSPITAL Fuzzy (name and state)
- Lobbying client: STAMFORD HOSPITAL Fuzzy (name and state)
- Nonprofit: STAMFORD HOSPITAL Fuzzy (name and state)
- Trademark owner: The Stamford Hospital Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2023 | General payment | 20 | $52,368 |
| 2023 | Research payment | 35 | $371,830 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| PFIZER INC. | 13 | $286,032 | 2023 |
| Sumitomo Pharma America, Inc. | 8 | $43,391 | 2023 |
| AstraZeneca Pharmaceuticals LP | 4 | $28,714 | 2023 |
| Stryker Corporation | 4 | $16,840 | 2023 |
| Genentech, Inc. | 3 | $16,018 | 2023 |
| Celgene Corporation | 2 | $13,705 | 2023 |
| E.R. Squibb & Sons, L.L.C. | 1 | $4,205 | 2023 |
| Tandem Diabetes Care, Inc. | 8 | $3,200 | 2023 |
| LEICA MICROSYSTEMS INC. | 1 | $2,949 | 2023 |
| Incyte Corporation | 2 | $2,682 | 2023 |
| EMD Serono, Inc. | 2 | $1,803 | 2023 |
| SEAGEN INC. | 1 | $1,533 | 2023 |
| Eli Lilly and Company | 1 | $1,282 | 2023 |
| CSL Behring | 1 | $500 | 2023 |
| Haemonetics Corporation | 1 | $500 | 2023 |
| ABBVIE INC. | 1 | $463 | 2023 |
| CONMED Corporation | 1 | $329 | 2023 |
| ZOLL Medical Corporation | 1 | $50 | 2023 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 35 | $371,830 |
| Charitable Contribution | 1 | $25,000 |
| Debt forgiveness | 4 | $13,653 |
| Long term medical supply or device loan | 3 | $6,515 |
| Space rental or facility fees (teaching hospital only) | 3 | $3,500 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 8 | $3,200 |
| Education | 1 | $500 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2023-12-31 | Stryker Corporation | $12,765 | Debt forgiveness | Cash or cash equivalent | 2023 | ||
| 2023-12-31 | Stryker Corporation | $3,516 | Long term medical supply or device loan | In-kind items and services | REMB Device, SURGICAL | 2023 | |
| 2023-12-31 | Stryker Corporation | $475 | Debt forgiveness | Cash or cash equivalent | 2023 | ||
| 2023-12-31 | ABBVIE INC. | $463 | Research payment | In-kind items and services | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Part | 2023 | |
| 2023-12-31 | Stryker Corporation | $83 | Debt forgiveness | Cash or cash equivalent | 2023 | ||
| 2023-12-30 | PFIZER INC. | $21,221 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2023 | |
| 2023-12-27 | Haemonetics Corporation | $500 | Education | Cash or cash equivalent | 2023 | ||
| 2023-12-21 | Incyte Corporation | $1,341 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxo | 2023 | |
| 2023-12-20 | EMD Serono, Inc. | $675 | Research payment | Cash or cash equivalent | BAVENCIO Drug, Oncology | PATRIOT II US Prospective 1st Line Maintenance of Avelumab in UC-2020 | 2023 |
| 2023-12-20 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-12-15 | PFIZER INC. | $34,257 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2023 | |
| 2023-12-08 | PFIZER INC. | $24,397 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2023 | |
| 2023-12-04 | AstraZeneca Pharmaceuticals LP | $25,000 | Charitable Contribution | Cash or cash equivalent | 2023 | ||
| 2023-11-29 | Incyte Corporation | $1,341 | Research payment | Cash or cash equivalent | A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kd Inhibitor Parsaclisib Plus Ruxolitinib in Participants | 2023 | |
| 2023-11-10 | PFIZER INC. | $7,580 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2023 | |
| 2023-11-01 | Sumitomo Pharma America, Inc. | $3,562 | Research payment | Cash or cash equivalent | ORGOVYX Drug, HORMONE THERAPY | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | 2023 |
| 2023-11-01 | Sumitomo Pharma America, Inc. | $2,864 | Research payment | Cash or cash equivalent | ORGOVYX Drug, HORMONE THERAPY | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | 2023 |
| 2023-11-01 | Sumitomo Pharma America, Inc. | $821 | Research payment | Cash or cash equivalent | ORGOVYX Drug, HORMONE THERAPY | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | 2023 |
| 2023-11-01 | Sumitomo Pharma America, Inc. | $410 | Research payment | Cash or cash equivalent | ORGOVYX Drug, HORMONE THERAPY | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | 2023 |
| 2023-10-17 | PFIZER INC. | $11,370 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2023 | |
| 2023-10-03 | PFIZER INC. | $7,541 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2023 | |
| 2023-09-20 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-09-14 | LEICA MICROSYSTEMS INC. | $2,949 | Long term medical supply or device loan | In-kind items and services | SENTIMAG Device, Devices | 2023 | |
| 2023-09-01 | Genentech, Inc. | $11,602 | Research payment | Cash or cash equivalent | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | 2023 | |
| 2023-08-30 | Sumitomo Pharma America, Inc. | $11,226 | Research payment | Cash or cash equivalent | ORGOVYX Drug, HORMONE THERAPY | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | 2023 |
| 2023-07-27 | PFIZER INC. | $2,461 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2023 | |
| 2023-07-25 | Genentech, Inc. | $2,510 | Research payment | Cash or cash equivalent | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | 2023 | |
| 2023-07-14 | ZOLL Medical Corporation | $50 | Long term medical supply or device loan | In-kind items and services | Device, DEFIBRILLATOR | 2023 | |
| 2023-07-08 | PFIZER INC. | $57,507 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2023 | |
| 2023-07-07 | EMD Serono, Inc. | $1,128 | Research payment | Cash or cash equivalent | BAVENCIO Drug, Oncology | PATRIOT II US Prospective 1st Line Maintenance of Avelumab in UC-2020 | 2023 |
| 2023-06-19 | CSL Behring | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2023 | ||
| 2023-06-07 | Tandem Diabetes Care, Inc. | $600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-05-31 | PFIZER INC. | $37,070 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2023 | |
| 2023-05-22 | CONMED Corporation | $329 | Debt forgiveness | In-kind items and services | 2023 | ||
| 2023-05-18 | Tandem Diabetes Care, Inc. | $600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-05-12 | PFIZER INC. | $37,108 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2023 | |
| 2023-05-11 | E.R. Squibb & Sons, L.L.C. | $4,205 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III Study - Breast Cancer HR Pos / HER2 Neg Neo adjuvant | 2023 |
| 2023-04-25 | SEAGEN INC. | $1,533 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2023 |
| 2023-04-24 | AstraZeneca Pharmaceuticals LP | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | IMFINZI Biological, Oncology | 2023 | |
| 2023-04-19 | Sumitomo Pharma America, Inc. | $8,894 | Research payment | Cash or cash equivalent | ORGOVYX Drug, HORMONE THERAPY | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | 2023 |
| 2023-04-18 | AstraZeneca Pharmaceuticals LP | $714 | Research payment | Cash or cash equivalent | IMFINZI Biological, Oncology | A Non-Interventional Primary Data Collection Study to Assess the Prevalence of PD-L1 High in First Line Metastatic and L | 2023 |
| 2023-04-03 | Genentech, Inc. | $1,906 | Research payment | Cash or cash equivalent | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | 2023 | |
| 2023-03-31 | PFIZER INC. | $11,289 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2023 | |
| 2023-03-24 | Celgene Corporation | $7,205 | Research payment | Cash or cash equivalent | Connect MM- The Multiple Myeloma Disease Registry | 2023 | |
| 2023-03-17 | AstraZeneca Pharmaceuticals LP | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ENHERTU Biological, Oncology | 2023 | |
| 2023-03-15 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-03-08 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-02-23 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-02-15 | PFIZER INC. | $19,146 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2023 | |
| 2023-02-08 | Eli Lilly and Company | $1,282 | Research payment | In-kind items and services | A PHASE 3 OPEN-LABEL RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB (LOXO-305) PLUS VENETOCLAX AND RITUXIMAB VERSUS VE | 2023 | |
| 2023-01-26 | Sumitomo Pharma America, Inc. | $10,612 | Research payment | Cash or cash equivalent | ORGOVYX Drug, HORMONE THERAPY | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | 2023 |
| 2023-01-26 | Sumitomo Pharma America, Inc. | $5,000 | Research payment | Cash or cash equivalent | ORGOVYX Drug, HORMONE THERAPY | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | 2023 |
| 2023-01-25 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-01-18 | Celgene Corporation | $6,500 | Research payment | Cash or cash equivalent | Revlimid Drug, Hematology | Connect MDS/AML - Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (A | 2023 |
| 2023-01-07 | PFIZER INC. | $15,079 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2023 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Stamford, CT, county Western Connecticut Planning Region, CT, state Connecticut; placed by its city name.
| Measure | Place (city or town) Stamford, CT | County Western Connecticut Planning Region, CT | State Connecticut |
|---|---|---|---|
| Population B01003 | 137,144 | 627,071 | 3,624,508 |
| Population, 2020 census P1 | 135,470 | - | 3,605,944 |
| Median age B01002 | 38.4 | 41.5 | 41.1 |
| Under 18 B01001 | 18.4% | 21.8% | 20.2% |
| 65 and over B01001 | 16.2% | 17.4% | 18.5% |
| Households B11001 | 55,291 | 235,379 | 1,434,007 |
| Foreign born B05002 | 31.3% | 23.8% | 15.7% |
| Median household income B19013 | $111,586 | $128,188 | $95,781 |
| Median family income B19113 | $126,493 | $161,625 | $122,706 |
| Per capita income B19301 | $67,068 | $82,266 | $55,915 |
| Poverty rate B17001 | 10.1% | 7.5% | 10.0% |
| Unemployment rate B23025 | 4.9% | 5.3% | 5.6% |
| Civilian labor force B23025 | 81,944 | 346,557 | 1,959,490 |
| Mean commute (minutes) B08013 | 28.5 | 30.8 | 26.5 |
| Bachelor's degree or higher B15003 | 51.7% | 55.5% | 42.5% |
| Housing units B25001 | 58,655 | 251,530 | 1,541,822 |
| Owner-occupied B25003 | 48.8% | 66.4% | 66.5% |
| Renters B25003 | 51.2% | 33.6% | 33.5% |
| Median home value B25077 | $624,400 | $652,900 | $366,900 |
| Median gross rent B25064 | $2,276 | $2,110 | $1,488 |
| White, not Hispanic B03002 | 43.2% | 58.6% | 61.9% |
| Black B03002 | 17.7% | 9.3% | 9.8% |
| Hispanic or Latino B03002 | 28.3% | 20.5% | 18.3% |
| Asian B03002 | 7.3% | 5.4% | 4.7% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Economy now FRED unemployment 5.1% in Sep 2026 (4.2% a year earlier); per capita personal income $102,307 in 2025, up 33% in five years (+7.1% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Stamford, CT.
Comments